The potential positive loop involving MET, NMDAR2B, and mTOR signaling, as well as the implications of these interactions in promoting pro-migratory functions, introduces a novel dimension to our understanding of cancer progression, paving the way for future research to explore the therapeutic possibilities arising from targeting these signaling pathways in cancer. This evidence concerns the gene MTOR and cancer.